A gene expression profile for vascular invasion can predict the recurrence after resection of hepatocellular carcinoma: A microarray approach

Annals of Surgical Oncology

Volumn 13, Issue 11, 2006, Pages 1474-1484

  Ho, Ming Chih ^a,b   Lin, Jen Jen ^b,c   Chen, Chiung Nien ^a,b   Chen, Chaur Chin ^b,d   Lee, Hsinyu ^b   Yang, Ching Yao ^a,b   Ni, Yen Hsuan ^a   Chang, King Jen ^a,b   Hsu, Hey Chi ^a   Hsieh, Fon Jou ^a,b   Lee, Po Huang ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c MING CHUAN UNIVERSITY   (Taiwan)

^d NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

Gene expression; Hepatocellular carcinoma; Liver resection; Microarray; Profiling; Recurrence; Vascular invasion

Indexed keywords

ADULT; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENOME ANALYSIS; HUMAN; LIVER CELL CARCINOMA; MALE; METASTASIS; MICROARRAY ANALYSIS; MOLECULAR RECOGNITION; POSTOPERATIVE PERIOD; PREDICTION; PROGNOSIS; VASCULAR TUMOR;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SURVIVAL RATE;

EID: 33750983646     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9057-1     Document Type: Article

References (54)

1. Barbara L, Benzi G, Gaiani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 1992; 16:132-7.
2. Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999; 229:322-30.
3. Imamura H, Seyama Y, Kokudo N, et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 2003; 138:1198-1206.
4. Esnaola N, Mirza N, Lauwers G, et al. Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan. Ann Surg 2003; 238:7119.
5. Jaeck D, Bachellier P, Oussoultzoglou E, Weber JC, Wolf P. Surgical resection of hepatocellular carcinoma. Post-operative outcome and long-term results in Europe: an overview. Liver Transpl 2004; 10(2 Suppl 1):S58-63.
6. Sun HC, Tang ZY. Preventive treatments for recurrence after curative resection of hepatocellular carcinoma - a literature review of randomized control trials. World J Gastroenterol 2003; 9:635-40.
7. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38:200-7.
8. Hanazaki K, Kajikawa S, Koide N, Adachi W, Amano J. Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis. Am J Gastroenterol 2001; 96:1243-50.
9. Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20:1527-36.
10. Yamanaka J, Yamanaka N, Nakasho K, et al. Clinicopathologic analysis of stage II-III hepatocellular carcinoma showing early massive recurrence after liver resection. J Gastroenterol Hepatol 2000; 15:1192-8.
11. Kaneko S, Urabe T, Kobayashi K. Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. Oncology 2002; 62(Suppl 1):69-73.
12. Xia JL, Yang BH, Tang ZY, Sun FX, Xue Q, Gao DM. Inhibitory effect of the angiogenesis inhibitor TNP-470 on tumor growth and metastasis in nude mice bearing human hepatocellular carcinoma. J Cancer Res Clin Oncol 1997; 123:383-7.
13. Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthey JN, Curley SA. Ellis LM. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003; 21:421-7.
14. Mathew J, Hines JE, Obafunwa JO, Burr AW, Toole K, Burt AD. CD44 is expressed in hepatocellular carcinomas showing vascular invasion. J Pathol 1996; 179:74-79.
15. Deli G, Jin CH, Mu R, Yang S, Liang Y, Chen D, Makuuchi M. Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues. World J Gastroenterol 2005; 11:960-3.
16. Sudo T, Utsunomiya T, Mimori K, et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 2005; 92:1754-8.
17. Park NH, Chung YH, Youn KH, et al. Close correlation of p53 mutation to microvascular invasion in hepatocellular carcinoma. J Clin Gastroenterol 2001; 33:397-401.
18. Okabe H, Satoh S, Kato T, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001; 61:2129-37.
19. Chen X, Cheung ST, So S, et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002; 13:1929-39.
20. Honda M, Kaneko S, Kawa H, Shirota Y, Kobayashi K. Differential gene expression between chronic hepatitis B and C hepatic lesion. Gastroenterology 2001; 120:955-66.
21. Shirota Y, Kaneko S, Honda M, Kawai HF, Kobayashi K. Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays. Hepatology 2001; 33:832-40.
22. Tackels-Horne D, Goodman MD, Williams AJ, et al. Identification of differentially expressed genes in hepatocellular carcinoma and metastatic liver tumors by oligonucleotide expression profiling. Cancer 2001; 92:395-405.
23. Xu L, Hui L, Wang S, et al. Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res 2001; 61:3176-3181.
24. Xu X-R, Huang J, Xu Z-G, et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci U S A 2001; 98:15089-94.
25. Hermanek P, Hendson DE, Hutter RVP. TNM supplement 1993: a commentary on uniform use Berlin: Springer; 1993.
26. Ikai I, Yamamoto Y, Yamamoto N, Terajima H, Hatano E, Shimahara Y, Yamaoka Y. Results of hepatic resection for hepatocellular carcinoma invading major portal and/or hepatic veins. Surg Oncol Clin N Am 2003; 12:65-75.
27. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, Speed TP. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002; 30:e15.
28. Tseng GC, Oh MK, Rohlin L, Liao JC, Wong WH. Issues in cDNA microarray analysis: quality filtering, channel normalization, model of variations and assessment of gene effects. Nucleic Acids Res 2001; 29:2549-57.
29. Hochberg Y, Tamhane AC. Multiple comparison procedures New York: Wiley; 1987.
30. Westfall PH, Young SS. Resampling-based multiple testing: examples and methods for P-value adjustment New York: Wiley; 1993.
31. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-6.
32. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95:14863-8.
33. Cover TM, Hart PE. "Nearest Neighbor Pattern Classification," IEEE Trans Inf Theory 1967; IT-13, 21-27.
34. Patt YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 2000; 23:319-21.
35. Hsu C, Chen CN, Chen LT, et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003; 65:242-9.
36. Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003; 361:923-9.
37. Suzuki K, Tsujitani S, Konishi I, Yamaguchi Y, Hirooka Y, Kaibara N. Expression of MAGE genes and survival in patients with hepatocellular carcinoma. Int J Oncol 1999; 15:1227-32.
38. Tahara K, Mori M, Sadanaga N, Sakamoto Y, Kitano S, Makuuchi M. Expression of the MAGE gene family in human hepatocellular carcinoma. Cancer 1999; 85:1234-40.
39. Tsukino H, Hanaoka T, Otani T, et al. hOGG1 Ser326Cys polymorphism, interaction with environmental exposures, and gastric cancer risk in Japanese populations. Cancer Sci 2004; 95:977-983.
40. Kim IJ, Ku JL, Kang HC, et al. Mutational analysis of OGG1, MYH, MTH1 in FAP, HNPCC and sporadic colorectal cancer patients: R154H OGG1 polymorphism is associated with sporadic colorectal cancer patients. Hum Genet 2004; 115:498-503.
41. Park J, Chen L, Tockman MS, Elahi A, Lazarus P. The human 8-oxoguanine DNA N-glycosylase 1 (hOGG1) DNA repair enzyme and its association with lung cancer risk. Pharmacogenetics 2004; 14:103-9.
42. Mukunyadzi P, Huang H, Liu K, Fan CY. Concomitant loss of mitochondria and the DNA repair protein hOGG1 in clear cell carcinoma of the kidney. Appl Immunohistochem Mol Morphol 2003; 11:334-38.
43. Nierodzik ML, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res 1992; 52:3267-72.
44. Palumbo JS, Degen JL. Fibrinogen and tumor cell metastasis. Haemostasis 2001; 31(Suppl 1):11-15.
45. Hernandez-Rodriguez NA, Correa E, Contreras-Paredes A, Green L. Evidence that thrombin present in lungs of patients with pulmonary metastasis may contribute to the development of the disease. Lung Cancer 1999; 26:157-67.
46. Chakraborty A, White SM, Lerner SP. Granulocyte colony-stimulating factor receptor signals for beta1-integrin expression and adhesion in bladder cancer. Urology 2004; 63:177-183.
47. Mengus G, Fadloun A, Kobi D, Thibault C, Perletti L, Michel I, Davidson I. TAF4 inactivation in embryonic fibroblasts activates TGF beta signalling and autocrine growth. EMBO J 2005; 24:2753-67.
48. Macoska JA. The progressing clinical utility of DNA microarrays. CA Cancer J Clin 2002; 52:50-9.
49. Wilkens L, Bredt M, Flemming P, Mengel M, Becker T, Klempnauer J, Kreipe H. Comparative genomic hybridization (CGH) and fluorescence in situ hybridization (FISH) in the diagnosis of hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2002; 9:304-11.
50. Fukuda S, Itamoto T, Nakahara H, et al. Clinicopathologic features and prognostic factors of resected solitary small-sized hepatocellular carcinoma. Hepatogastroenterology 2005; 52:1163-7.
51. Ijichi M, Takayama T, Matsumura M, Shiratori Y, Omata M, Makuuchi M. Alpha-fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study. Hepatology 2002; 35:853-860.
52. Witzigmann H, Geissler F, Benedix F, et al. Prospective evaluation of circulating hepatocytes by alpha-fetoprotein messenger RNA in patients with hepatocellular carcinoma. Surgery 2002; 131:34-43.
53. Mou DC, Cai SL, Peng JR, et al. Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells. Br J Cancer 2002; 86:110-16.
54. Waguri N, Suda T, Nomoto M, et al. Sensitive and specific detection of circulating cancer cells in patients with hepatocellular carcinoma; detection of human telomerase reverse transcriptase messenger RNA after immunomagnetic separation. Clin Cancer Res 2003; 9:3004-11.